MAP2K6 and rheumatoid arthritis: Therefore, blocking MKK3 or MKK6 shows promising therapeutic efficacy in vivo in mouse models, indicating the pharmacological potential of MKK3 and MKK6 inhibitors for MLS/FLS-targeted therapy of RA (50, 51).